Nifty Pharma Sees Bullish Momentum in Three Stocks
Three Nifty Pharma stocks, including Biocon and Piramal Pharma, recently shifted to bullish momentum as the sector accelerates as the #1 ranked leader.
- Visit the stock pages: BIOCON, PPLPHARMA, CIPLA
- Sector Nifty Pharma Sector , which ranks #1 for Relative Strength (Altra Sector score of 92.0 with bullish regime.)
The Nifty Pharma sector has captured attention as it stands out as the #1 ranked sector, demonstrating strong bullish momentum with an Altra Sector score of 92.0. This indicates not only a robust internal strength but also a significant acceleration, evidenced by its 4-week relative strength trend of +2.92, a healthy EMA spread of 5.62, and an RS RSI of 71.4. This confirmed leadership position within the market sets a compelling backdrop for individual stock movements.
To provide context for these insights, the Altra Score is a 0-100 momentum rating for individual stocks, calculated from the alignment of Exponential Moving Averages (EMAs) and the trend of the Relative Strength Index (RSI) across daily, weekly, and monthly timeframes. A higher score signifies more bullish momentum. The Altra Market score, on the other hand, offers a broader view of market health by measuring the percentage of stocks trading above key EMAs. Lastly, the Altra Sector score applies this analysis to sectors, providing a momentum reading and a relative-strength rank against other sectors.
Today, we observe three Nifty Pharma constituents – Biocon, Piramal Pharma, and Cipla – that have each registered notable bullish shifts in their Altra Scores, signaling potential momentum acceleration within this leading sector. The broader market itself is showing signs of improvement, with the Altra Market score at 60.7 and market breadth indicators showing 56.0% of stocks above their 20-day and 50-day EMAs, and 54.0% above their 200-day EMA. The advance/decline ratio stands at 42/8, with the 15-day score trend at +3.5, suggesting a selective environment where high-quality setups are favored.
BIOCON (Biocon Ltd.)
Biocon Ltd. experienced a significant momentum shift, with its Altra Score climbing from 43.4 to 83.0 on July 10, 2026, transitioning from a Neutral to a Strong Bullish classification. This substantial jump places Biocon firmly in a high-momentum phase. The stock is currently trading above its key EMAs, a classic sign of upward trend confirmation. Its daily, weekly, and monthly RSI readings are all in healthy territory at 52.98, 59.41, and 59.29 respectively, indicating underlying buying interest across timeframes. Furthermore, Biocon has maintained a top-down aligned momentum structure, a factor often associated with sustained price movement. A bullish 8-week and 30-week EMA crossover, recorded on September 1, 2023, continues to underpin this long-term positive outlook, suggesting that the recent score acceleration is building on an established foundation.
PPLPHARMA (Piramal Pharma Ltd.)
Piramal Pharma Ltd. has also demonstrated a compelling shift in its momentum profile, moving from a Bearish 36.5 to a Bullish 79.2 on July 9, 2026, and currently standing at a Strong Bullish 82.4. This impressive reversal underscores a significant change in its underlying technical strength. Piramal Pharma is trading above its key EMAs, affirming a constructive price action. Its daily RSI is at 58.85, weekly at 56.4, and monthly at 44.09. Crucially, the stock registered a bullish 8-week and 30-week EMA crossover on July 3, 2026, a very recent signal that typically precedes strong momentum phases. This, combined with its top-down aligned momentum, suggests a concerted upward movement that aligns with the accelerating Nifty Pharma sector.
CIPLA (Cipla Ltd.)
Cipla Ltd. rounds out this trio of Nifty Pharma stocks displaying improved momentum, with its Altra Score rising from 58.9 to 67.3 on July 9, 2026, moving from Neutral to Bullish. Currently, Cipla maintains a Bullish Altra Score of 65.2. The stock is positioned above its key EMAs, a technical posture that supports its newfound bullish classification. RSI readings across timeframes are balanced, with daily at 56.95, weekly at 57.56, and monthly at 49.82, suggesting steady participation. While Cipla experienced a bearish 8-week and 30-week EMA crossover on December 19, 2025, the recent Altra Score increase and current EMA placement indicate that short-to-medium term momentum has shifted to a more favorable stance. Its top-down aligned momentum suggests that this bullish turn is consistent across multiple timeframes, providing a robust signal within the leading pharma sector.
What is the Altra Score? The Altra Score is AltraOne's proprietary momentum score for individual stocks, ranging from 0 to 100. It measures EMA structure and RSI momentum across multiple timeframes. A score above 60 is Bullish, below 40 is Bearish, and 40–60 is Neutral. The score is updated every trading day after market close based on end-of-day data.
Explore the full Signal History on AltraOne to see every EMA crossover signal across your watchlist — going back 52 weeks. The weekly EMA crossover is AltraOne's highest-conviction intermediate momentum signal; the Signal History page lets you track how these have played out over time.
Altra Score is a momentum indicator reflecting EMA alignment and RSI trend across daily, weekly, and monthly timeframes. It is not investment advice. Past momentum does not guarantee future performance. Please consult a SEBI-registered advisor before making investment decisions.